RxDoctor Payments Data

Jay Padratzik, MD

Obstetrics & Gynecology · Saint Louis, MONPI 1467427161

Payments from drug & device makers

$5,263in general payments, 2019–2025

Across 293 payments — averaging $17.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$799
  • Mayne Pharma Commercial LLC$759
  • Astellas Pharma US Inc$469
  • Novo Nordisk$397
  • Exeltis, USA Inc.$278
  • Hologic Sales And Service, LLC$273
  • plus $2K from 31 others

What the payments were for

  • Food & beverage$5,18899%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,263 in reported general payments places this provider in the 90th percentile of 750 obstetrics & gynecology providers in Missouri.

See all obstetrics & gynecology providers in Missouri

Medicare billing

Part B allowed, 2024
$14,052
Medicare patients
111
Services billed
208

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated49$14,763
MyrbetriqMirabegron15$9,632
Estradiol156$5,943
PremproEstrogen,con/M-Progest Acet14$3,405
CombipatchEstradiol/Norethindrone Acet11$2,676
Estradiol (Once Weekly)Estradiol24$2,525
ValacyclovirValacyclovir Hcl41$2,453
Estradiol (Twice Weekly)Estradiol25$2,224
Raloxifene Hcl38$1,215
DottiEstradiol15$805
ProgesteroneProgesterone, Micronized36$710
Medroxyprogesterone Acetate15$666
Clobetasol Propionate19$485
Solifenacin Succinate18$403
Alprazolam36$355

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin, Prempro$248$18,16863 claims
Astellas Pharma US IncMyrbetriq$469$9,63215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 750 obstetrics & gynecology providers in Missouri.

Other obstetrics & gynecology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →